Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

Recruiting now · Phase 1/Phase 2

Conditions studied: Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma

In brief

This research is designed to determine if experimental treatment with AZD5863, a T cell-engaging bispecific antibody that targets Claudin 18.2 (CLDN18.2) and CD3, is safe, tolerable and has anti-cancer activity in patients with advanced solid tumors.

Key facts

Study ID
NCT06005493
Run by
AstraZeneca
People needed
280
Starts
2023-07-11
Expected to finish
2027-07-16
Last updated by the study team
2026-02-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.